Clinical Trial Update: Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ribociclib as adjuvant therapy in hormone receptor-positive, HER2-negative early breast cancer with residual disease after neoadjuvant …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING